emtricitabine/tenofovir alafenamide (FTC/TAF)

Recommended as component of initial regimen for most people
Nucleoside "Nuke"

Standard Dose

One tablet once daily, without regard to food. Tablet contains 200 mg emtricitabine and 25 mg tenofovir alafenamide.

For adults and children weighing at least 55 pounds (25 kg). Crushing or splitting tablets has not been studied and is not recommended; TAF is soluble in water, but has a bitter and burnt aromatic flavor profile.

Take a missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. Descovy should not be used if CrCl is less than 30 mL/min or if you are on dialysis. In children weighing less than 77 pounds, taking Descovy with a boosted HIV protease inhibitor medication is not recommended. Descovy was approved for HIV prevention (pre-exposure prophylaxis, or PrEP) in October 2019.


Gilead Sciences, Inc.
(800) GILEAD-5 (445–3235)



Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments